Clinical Innovation

Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…